Remepy Overview
Remepy is pioneering hybrid drugs, and redefining combination therapy. Its mission is to bring better personalized care to patients. Remepy’s Digital molecules are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. Its Digital molecules include digitized, standardized, evidence-based interventions, designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. The company addresses disease end-points as well as side-effects and disease comorbidities. Remepy partners with pharma companies to bring Hybrid Drugs to market that will combine Remepy’s Digital Molecule and traditional drug components.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation
Remepy is advancing its RMPY-008 app by incorporating adaptive sequencing, journaling tools, and phenotyping capabilities. The company is exploring two regulatory pathways to integrate software and drug into a single therapeutic entity. The first pathway involves a combination product approach, while the second utilizes the FDA’s Prescription Drug Use-Related Software (PDURS) pathway. The RMPY-008 app delivers its protocol through cognitive-emotional tasks and sensory modulation, aiming to enhance therapeutic outcomes.
growth-positive
Remepy's Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline
Remepy, a pioneer in hybrid drugs integrating digital and pharmacological interventions, announced that its app-based intervention, RMPY-008, demonstrated significant modulation of inflammatory blood biomarkers in a clinical trial. The study, involving 103 adults, showed that the digital intervention reduced depressive symptoms and improved brain connectivity in individuals with subjective cognitive decline. The findings suggest that RMPY-008 can modulate both brain and immune functions, offering a new therapeutic modality. The app achieved high adherence and engagement, with participants showing sustained benefits. Remepy is commercializing its platform in collaboration with pharmaceutical partners, focusing initially on Parkinsons disease, with plans to expand into fertility, oncology, and immunology.
Product StagePartners
growth-positive
Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.
Remepy, a company co-founded by Dr. Michal Tsur, is pioneering the development of hybrid medications, combining digital applications with traditional drugs. At the 2024 Globes Israel Business Conference, Tsur highlighted the potential of these medications, particularly for Parkinsons disease, following a successful clinical trial. The company aims to revolutionize the pharmaceutical industry by integrating digital treatment protocols with chemical elements, enhancing treatment accessibility and effectiveness. Additionally, Tsur is exploring the establishment of a new airline to offer affordable flights, addressing the current scarcity and high cost of air travel to and from Israel. This initiative reflects the broader trend of high-tech entrepreneurship addressing public sector gaps. Tsur emphasizes the importance of private sector innovation in improving public life, advocating for proactive solutions to societal challenges.
growth-positive
Israeli Startup Combines Software With Medicine To Transform Pharma
Remepy, an Israeli startup, is pioneering the development of hybrid drugs by combining software with traditional medicine. The company has successfully closed a $10 million seed investment round, bringing its total funding to $15 million. The investment was led by NFX and included several other venture firms. Remepy aims to standardize and personalize therapeutic interventions using digital molecules, which have shown promising results in early clinical studies. The company plans to target diseases like Parkinson’s, neurodegenerative diseases, and cancer. Remepy has also announced new board members, including Danny Bar Zohar from Merck and former Israeli Prime Minister Naftali Bennett. The companys approach could potentially halve the time required to bring new drugs to market.
InvestmentManagement ChangesProduct Stage
growth-positive
Remepy raises $10 million Seed round to bring first hybrid drug to market | CTech
Israeli startup Remepy has raised $10 million in a seed investment round, bringing its total funding to $15 million. The round was led by NFX and included participation from Vine Ventures, Psymed Ventures, Supernode Ventures, and Firstime Ventures, among others. Remepy is developing hybrid drugs that combine traditional drugs with its digital molecules, therapeutic interventions that trigger physiological effects through the brain. The company has shown promising results in human studies for Oncology, MCI, and Parkinson’s Disease. Dr. Danny Bar Zohar, Merck’s Global head of R&D and Chief Medical Officer, will be joining the board.
InvestmentManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $25M |
| Last funding | $10M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 9 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.remepy.com/ |
| Careers | Careers page |
Locations
Ramat Gan, Israel
Photos & Videos
No files yet
